DEALS
Zhong Lun Assists Wuxi PharmaTech with Privatization
Zhong Lun Assists Wuxi PharmaTech with Privatization
Release time：2016-01-14
Voice Announcements
On 10 December 2015, WuXi PharmaTech (Cayman) Inc (NYSE:WX), announced completion of its privatization merger for cash consideration of approximately US$3.3 billion. WuXi PharmaTech is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries with operations in China and the United States. As a result of the merger, the company will be delisted from the New York Stock Exchange.
Partner Steve Zhao and associates Rose He and Liu Rongmei of Zhong Lun Law Firm worked as China counsel to the special committee of WuXi PharmaTech’s board of directors charged with evaluating the merger plan.